Deniel Mero

Deniel is the Editor of Last Financier, a commentary and subscription-based investment newsletter focused on the latest market trends and actionable trades in high-tech and healthcare. His investment research, with notable calls in 3D Printing, communication technologies and emerging oncology names, has been syndicated throughout leading financial media platforms across the web.

Recent Articles By The Author

Sentiment for Advaxis Back to Bullish With Broadfin and Inovio Deal

Sentiment for Advaxis Back to Bullish With Broadfin and Inovio Deal

Advaxis back on investor good books after Broadfin healthcare fund doubled their position after stock's 40% decline

Advaxis Receives Vote of Confidence From Hedge Fund Adage Capital

Advaxis Receives Vote of Confidence From Hedge Fund Adage Capital

Adage Capital averaged their Advaxis position up at a price 150% higher than their last offering. What is the hedge fund seeing in the immunotherapy company?

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.

Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro

Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro

Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.

Advaxis Surges Higher on Additional Institutional Interest

Advaxis Surges Higher on Additional Institutional Interest

Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.